Metrorrhagia
3
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
BayerLEVERKUSEN, Germany
3 programs3
EV/DNGPhase 31 trial
Estradiol valerate/DienogestPhase 31 trial
Estradiol valerate/DienogestPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
BayerEV/DNG
BayerEstradiol valerate/Dienogest
BayerEstradiol valerate/Dienogest
Clinical Trials (3)
Total enrollment: 760 patients across 3 trials
Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding
Start: Jun 2012Est. completion: Jun 2015339 patients
Phase 3Completed
Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding
Start: Feb 2006Est. completion: May 2008231 patients
Phase 3Completed
Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding
Start: Dec 2005Est. completion: May 2008190 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 late-stage (Phase 3) programs, potential near-term approvals
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.